Kleiner Perkins backs iZumi Bio's stem cell research

06/17/2008 | San Francisco Chronicle

Kleiner Perkins Caufield & Byers will invest in iZumi Bio, a biotech firm working on reprogramming adult cells to regain the properties of embryonic stem cells. IZumi announced Monday that it will collaborate with the J. David Gladstone Institutes in San Francisco to focus on research involving "induced pluripotent stem cells."

View Full Article in:

San Francisco Chronicle

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations